Portfolio companies news

08 October 2015

Celtaxsys Begins US Enrollment for Phase 2 Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today the commencement of the US arm of an international phase 2 clinical trial for its flagship compound, acebilustat, in patients with cystic fibrosis (CF). The study will be conducted at approximately 60 sites inthe United States and European Union, with the EU sites anticipated to begin enrollment early 2016. 

06 October 2015

Neothetics Announces Issuance by USPTO of Additional Patent Directed to LIPO-202 Lead Clinical Asset

Neothetics, Inc.  (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the issuance of U.S. Patent No. 9,132,084 by the United States Patent and Trademark Office (USPTO). This marks issuance of the company's third  United States  patent in its portfolio that is directed to  Neothetics'  lead asset, LIPO-202, the first non-invasive injectable drug candidate for reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects. This particular patent is directed to formulations and methods for reducing adipose tissue using LIPO-202. 

02 October 2015

Range of refractive independence and mechanism of action of a corneal shape–changing hydrogel inlay: Results and theory

Roger F. Steinert, MD, Jim Schwiegerling, PhD, Alan Lang, PhD, Adam Roy, MS, Keith Holliday, PhD, Enrique Barragán Garza, MD, Arturo S. Chayet, MD / Journal of Cataract Refractive Surgery

The clinical data presented show the corneal inlay significantly improved near and intermediate uncorrected visual acuities across a 2.0 D range of preoperative refractive range (-0.5 D to +1.50 D) and age-related reading ADD powers between +1.50 D to +2.50 D.  Near task performance was also significantly improved in good and dim light compared to preoperative levels.  In the treated eye, the mean postoperative visual acuities were: 20/25 (near), 20/25 (intermediate), and 20/32 (distance).   The clinical outcomes are explained by the center-near power profile of the cornea induced by the shape-changing inlay providing zones within the pupil for good near, intermediate, and distance image quality.  And this thesis is confirmed by optical ray-trace predictions of visual acuity over this preoperative refractive range at distance, intermediate and near. 

01 October 2015

Celtaxsys to Present Clinical Data on Oral Acebilustat at North American Cystic Fibrosis Conference: Key Inflammation Biomarkers Reduced in CF Patients

Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today that results from a clinical trial of acebilustat in CF patients will be presented at the 29th North American Cystic Fibrosis Conference (NACFC) in Phoenix Oct 8-10, 2015.

30 September 2015

Neothetics Initiates Study to Evaluate the Safety of LIPO-202 for Body Contouring in Obese Subjects

Neothetics, Inc.  (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the initiation of the safety study, LIPO-202-CL-21, of LIPO-202, the first non-invasive injectable drug candidate for reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects. 

28 September 2015

Syndax and Merck Announce First Patients Dosed in Phase 1b/2 Clinical Trial of Entinostat and Keytruda®

Syndax Pharmaceuticals, Inc. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the dosing of the first patients in the Phase 1b/2 clinical trial of Syndax’s entinostat in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with non-small cell lung cancer (NSCLC) or melanoma. The clinical trial, designated ENCORE 601 by Syndax and KEYNOTE 142 by Merck, is evaluating the safety, tolerability and efficacy of entinostat, an oral, small molecule that targets immune regulatory cells, combined with KEYTRUDA, an anti-programmed cell death protein 1 (anti-PD-1) antibody.

28 September 2015

Neothetics Expands Its Board of Directors With Appointments of Jeffrey Nugent and Hani Zeini

Neothetics, Inc.  (NASDAQ:NEOT) today announced that it has named  Jeffrey Nugent  and Hani Zeini to its Board of Directors.

28 September 2015

ReVision Optics Files Final Module of FDA Premarket Approval Application for Raindrop® Near Vision Inlay for the Correction of Presbyopia

ReVision Optics, Inc. (RVO®), a leader in implantable presbyopia-correcting corneal inlay technology, announces the submission to the U.S. Food and Drug Administration (FDA) of the fourth and final module of the company’s Premarket Approval (PMA) application for the Raindrop® Near Vision Inlay. The Raindrop is a microscopic hydrogel inlay designed to correct presbyopia, thus reducing or even eliminating the need for reading glasses. The fourth module includes clinical data from more than 300 subjects who have been followed for at least 24 months post-procedure.

24 September 2015

Clearside Biomedical, Inc. Announces 50th Patient Enrolled Using Suprachoroidal Drug Administration

Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the retina and choroid, today announced the enrollment of the 50th patient using Clearside’s proprietary ophthalmic drug administration platform for delivering drugs to the suprachoroidal space (SCS).

14 September 2015

Atlas Genetics Ltd: Grant of Key US Patent

Atlas Genetics Ltd ("Atlas Genetics" or the "Company"), the ultra-rapid 'test and treat' molecular diagnostics company, today announces the granting of a key patent in its intellectual property portfolio.